EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Five-Year Late Toxicity After Ultra-Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost: A Prospective Multicenter Cohort Study

Maia Dzhugashvili, Escarlata Lopez, Jaume Fernández-Ibiza, Ana Serradilla, Antonio Seral, Sigfredo Elias Romero Zoghbi, Graciela García, Kirill Matskov Malinochka, Lisellot Torres, Daniela Gonsalves, José Begara, Ana Belén Bezares und 15 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026-10

DOI: 10.1016/j.ijrobp.2026.09.020 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-10. Verfasst von Maia Dzhugashvili und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation, GenesisCare, Madrid, Spain. Electronic address: maiadz@icloud.com. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Ultra-hypofractionated whole-breast radiation therapy has become an accepted option for early breast cancer, but evidence on the incorporation of a simultaneous integrated boost within a 5-fraction schedule remains limited. The present study evaluated 5-year late side effects after whole-breast irradiation with a simultaneous integrated boost delivered in 5 fractions in a prospective multicenter cohort. METHODS AND MATERIALS: This prospective, nonrandomized, multicenterWhole-breast irradiation was delivered at 26 Gy in 5-day fractions, and 157 patients received a simultaneous integrated boost to 29 Gy in 5 fractions. The primary endpoint was late normal-tissue side effects in the simultaneous integrated boost subgroup, assessed prospectively with clinical examination, photographic documentation, and LENT-SOMA (Late Effects of Normal Tissues-Subjective, Objective, Managment, Analytic) scoring. Comparisons with patients treated without a boost were exploratory. RESULTS: Median follow-up was 64.7 months in both the overall cohort and the simultaneous integrated boost subgroup, and 221 of 242 patients completed the scheduled 5-year visit. In the simultaneous integrated boost subgroup, cumulative any-grade pain was reported in 14.6% of patients at 5 years, and cumulative any-grade fibrosis in 8.9%. Other late side effects were uncommon, including breast edema in 5.1%, arm edema in 0.6%, atrophy in 1.9%, and telangiectasia in 0.6%; no ulceration was observed. In exploratory unadjusted analyses, pain was more frequent in the simultaneous integrated boost group than in the no-boost group, whereas no significant differences were observed for other late side effects. Chemotherapy receipt was also associated with persistent pain in exploratory analyses. CONCLUSIONS: Whole-breast irradiation with a 29 Gy simultaneous integrated boost in 5 fractions achieved low rates of objective late side effects and reassuring oncologic outcomes after more than 5 years while shortening treatment to a single 1-week course compared with sequential or moderately hypofractionated schedules. Persistent low-grade breast pain was more frequent with the boost, but nonrandomized allocation and its association with chemotherapy preclude causal attribution, supporting continued, careful use in selected patients alongside further prospective, randomized studies with baseline symptom assessment.

Autor:innen und Institutionen

  • Department of Radiation, GenesisCare, Madrid, Spain. Electronic address: maiadz@icloud.com.
  • Department of Radiation, GenesisCare, Madrid, Spain; Faculty of Medicine, Universidad Europea de Madrid, Madrid, Spain.
  • Department of Radiation, GenesisCare, Madrid, Spain.
  • Department of Radiation Oncology, Complejo Hospitalario de Jaén, Jaen, Spain.
  • Hospital Nuestra Señora de Sonsoles (HNSS), Complejo Asistencial de Ávila, Avila, Spain.
  • Department of Radiation Oncology, Hospital General Universitario de Elche, Elche, Spain.

Zitieren

APA

Dzhugashvili, M., Lopez, E., Fernández-Ibiza, J., Serradilla, A., Seral, A., Romero Zoghbi, S. E., García, G., Malinochka, K. M., Torres, L., Gonsalves, D., Begara, J., Bezares, A. B., Flores, Á., Mateos, M., Esteban, D., Rivas, D., Andreescu, J., Fernandez, C., Ocanto, A., …, & Couñago, F. (2026). Five-Year Late Toxicity After Ultra-Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost: A Prospective Multicenter Cohort Study. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.09.020

Vancouver

Dzhugashvili M, Lopez E, Fernández-Ibiza J, Serradilla A, Seral A, Romero Zoghbi SE, et al. Five-Year Late Toxicity After Ultra-Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost: A Prospective Multicenter Cohort Study. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.09.020

BibTeX
@article{Dzhugashvili2026,
  author = {Dzhugashvili, Maia and Lopez, Escarlata and Fernández-Ibiza, Jaume and Serradilla, Ana and Seral, Antonio and Romero Zoghbi, Sigfredo Elias and García, Graciela and Malinochka, Kirill Matskov and Torres, Lisellot and Gonsalves, Daniela and Begara, José and Bezares, Ana Belén and Flores, Álvaro and Mateos, María and Esteban, David and Rivas, Daniel and Andreescu, Jon and Fernandez, Castalia and Ocanto, Abrahams and Aakki, Loubna and Góngora, Francisco and Gómez, Alberto and Melian, Eduardo and Troca, Juan José De la Cruz and Poortmans, Philip and Barcia, Juan A and Couñago, Felipe},
  title = {Five-Year Late Toxicity After Ultra-Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost: A Prospective Multicenter Cohort Study},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2026.09.020}
}
Kostenlos starten →